Evaluation of Continuous Glucose Monitoring in Patients With ACS and Type 2 Diabetes in ICU (NCT04822740) | Clinical Trial Compass
TerminatedNot Applicable
Evaluation of Continuous Glucose Monitoring in Patients With ACS and Type 2 Diabetes in ICU
Stopped: loss of equipment supplier
France2 participantsStarted 2022-12-07
Plain-language summary
The investigators hypothesize that the use of a continuous glucose monitoring system (CGMS) can reduce glycemic variability assessed by coefficient of variation (CV) during the acute phase of acute coronary syndrome (ACS) in patients with diabetes treated by insulin infusion.
The purpose of this project is to assess the impact of the use of CGMS on glycemic variability in diabetic patients with ACS .
This is a randomized, multicenter (2 centers), open study. The patients included, as soon as possible, after admission will be randomized before the beginning of insulin therapy with intravenous insulin .
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient over 18 years old admitted to Cardiac Intensive Care Unit (CICU for acute coronary syndrome (ACS):
✓. patient with type 2 diabetes (defined according to the American Diabetes Association (ADA) recommendations) known with:
✓. Patient who has not yet received insulin therapy with intravenous insulin since admission
✓. Signed informed consent
✓. oral and written comprehension of the French language